Repertoire Immune Medicines

Repertoire Immune Medicines is a clinical-stage biotechnology company founded in 2016 and based in Cambridge, Massachusetts. The company focuses on harnessing the power of T cells to develop innovative therapies aimed at preventing, treating, and curing cancer, autoimmune conditions, and infectious diseases. Repertoire Immune Medicines is actively engaged in experimental clinical trials that utilize autologous T cells primed against specific cancer antigens and linked to IL-15. Additionally, the company specializes in the characterization of T cell receptor (TCR)-antigen pairs, allowing for the rational design and development of targeted immune medicines. These efforts are designed to enhance the human immune system's capabilities, providing new treatment options for patients with serious health challenges.